• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by SciSparc Ltd.

    12/13/22 6:22:30 AM ET
    $SPRC
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $SPRC alert in real time by email
    SC 13G 1 ea169994-13gscisparc_clear.htm SCHEDULE 13G

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

     

    SCHEDULE 13G

     

    Under the Securities Act of 1934

     

    Clearmind Medicine Inc.

    (Name of Issuer)

     

    Common Shares, no par value

    (Title of Class of Securities)

     

    1850532047

    (CUSIP Number)

     

    November 17, 2022

    (Date of event which requires filing of this statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

      ☐ Rule 13d-1(b)
         
      ☒ Rule 13d-1(c)
         
      ☐ Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required on the remainder of this cover page shall not be deemed to be “filed” for purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     

    1

    NAME OF REPORTING PERSON

     

    SciSparc Ltd.

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ☐

    (b) ☒

    3

    SEC USE ONLY

     

     

    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Israel

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH

    5

    SOLE VOTING POWER

     

    230,769(1)

    6

    SHARED VOTING POWER

     

    0

    7

    SOLE DISPOSITIVE POWER

     

    230,769 (1)

    8

    SHARED DISPOSITIVE POWER

     

    0

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    230,769(1)

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    ☐

     

     

    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

    9.33% (2)

    12

    TYPE OF REPORTING PERSON

     

    CO

     

    (1) Consists of 230,769 Common Shares of the issuer held directly by SciSparc Ltd.
       
    (2) Based on 2,473,617 Common Shares issued and outstanding as of November 16, 2022, based on information received from the Issuer.

     

    2

     

     

    Item 1(a) Name of Issuer:

     

    Clearmind Medicine Inc. (the “Issuer”)

     

    Item 1(b) Address of Issuer’s Principal Executive Offices:

     

    101 – 1220 West 6th Avenue, Vancouver, British Columbia, Canada 

     

    Item 2(a) Name of Person Filing:

     

    SciSparc Ltd.

     

    Item 2(b) Address or Principal Business Office or, if none, Residence:

     

    20 Raul Wallenberg Street, Tower A, Tel Aviv 6971916 Israel 

     

    Item 2(c) Citizenship:

     

    Israel

     

    Item 2(d) Title of Class of Securities:

     

    Common Share, no par value

     

    Item 2(e) CUSIP Number:

     

    1850532047 

     

    Item 3 If this statement is filed pursuant to Rule 13d-1(b), or 13d-2(b) or (c), check whether the person filing is:

     

    Not applicable.

     

    Item 4 Ownership.

     

    See items 5-11 of the cover pages hereto for beneficial ownership, percentage of class and dispositive power of the Reporting Person, which is incorporated herein.

     

    Item 5 Ownership of Five Percent or Less of a Class.

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following ☐

     

    Item 6 Ownership of More than Five Percent on Behalf of Another Person.

     

    Not applicable.

     

    Item 7 Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

     

    Not applicable.

     

    Item 8 Identification and Classification of Members of the Group.

     

    Not applicable.

     

    Item 9 Notice of Dissolution of Group.

     

    Not applicable.

     

    Item 10 Certifications.

     

    Not applicable.

     

    3

     

     

    SIGNATURES

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a-11.

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated: December 13, 2022 SCISPARC LTD.
         
    By: /s/ Oz Adler
    Name: Oz Adler
    Title: Chief Executive Officer & Chief Financial Officer

     

     

    4 

     

     

    Get the next $SPRC alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $SPRC

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $SPRC
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Clearmind Medicine Announces Publication of International Patent Application for Novel Combination Therapy Targeting Obesity and High Blood Sugar

    Vancouver, Canada, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (NASDAQ:CMND), (FSE: CWY0) ("Clearmind" or the "Company"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today announced the publication of an international patent application under the Patent Cooperation Treaty (PCT) as part of its ongoing collaboration with SciSparc Ltd. (NASDAQ:SPRC) ("SciSparc"), a specialty clinical-stage pharmaceutical company developing therapies for central nervous system disorders. The patent application published under the European Patent Office covers an innovative combinatio

    8/7/25 7:32:00 AM ET
    $CMND
    $SPRC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SciSparc-Clearmind Collaboration Leads to Publication of International Patent Application for Novel Combination Therapy Targeting Obesity and High Blood Sugar

    TEL AVIV, Israel, Aug. 07, 2025 (GLOBE NEWSWIRE) -- SciSparc Ltd. (NASDAQ:SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the central nervous system, announced today that its collaboration with Clearmind Medicine Inc. (NASDAQ:CMND) ("Clearmind") has led to the publication of an international patent application under the Patent Cooperation Treaty (PCT). The patent application published under the European Patent Office covers an innovative combination therapy of Clearmind's proprietary 5-methoxy-2-aminoindane (MEAI) and SciSparc's Palmitoylethanolamide (PEA) for the treatment

    8/7/25 7:32:00 AM ET
    $CMND
    $SPRC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SciSparc Announces Updates Regarding Proposed Merger; Form F-4 Registration Statement Has Been Declared Effective by SEC

    TEL AVIV, Israel, July 30, 2025 (GLOBE NEWSWIRE) -- SciSparc Ltd. (NASDAQ:SPRC) (the "Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, announces additional progress in connection with the proposed merger with AutoMax Motors Ltd., a leading vehicles importer and the exclusive importer of Anhui Jianghuai Automobile Group Corp., Ltd.-manufactured electric vehicles in Israel ("AutoMax").  As previously disclosed, in April 2024, SciSparc and AutoMax entered into a merger agreement, as amended, under which, SciSparc will acquire 100% of the share capital of AutoMax by way of a r

    7/30/25 4:34:00 PM ET
    $SPRC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SPRC
    SEC Filings

    View All

    SEC Form 6-K filed by SciSparc Ltd.

    6-K - SciSparc Ltd. (0001611746) (Filer)

    8/8/25 6:05:29 AM ET
    $SPRC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by SciSparc Ltd.

    6-K - SciSparc Ltd. (0001611746) (Filer)

    7/31/25 4:05:16 PM ET
    $SPRC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form EFFECT filed by SciSparc Ltd.

    EFFECT - SciSparc Ltd. (0001611746) (Filer)

    7/31/25 12:15:12 AM ET
    $SPRC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SPRC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by SciSparc Ltd.

    SC 13G - SciSparc Ltd. (0001611746) (Subject)

    3/6/24 5:02:18 PM ET
    $SPRC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by SciSparc Ltd.

    SC 13G - SciSparc Ltd. (0001611746) (Filed by)

    12/13/22 6:22:30 AM ET
    $SPRC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by SciSparc Ltd. (Amendment)

    SC 13G/A - SciSparc Ltd. (0001611746) (Subject)

    5/9/22 4:08:30 PM ET
    $SPRC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SPRC
    Leadership Updates

    Live Leadership Updates

    View All

    SciSparc Makes Another Step Towards Unlocking Potential Value Appoints New Strategy and Business Development VP

    As part of the Company's corporate restructuring plan, Mr. Yaki Baranes will facilitate identifying new business opportunities TEL AVIV, Israel, May 30, 2023 (GLOBE NEWSWIRE) -- SciSparc Ltd. (NASDAQ:SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, today announced that as part of its restructuring plans to unlock value for shareholders, it has appointed a new Vice President of Strategy and Business Development, Mr. Yaki Baranes, to structure business strategies and facilitate identifying new business opportunities. Mr. Baranes is a business strategy expert with a

    5/30/23 8:40:00 AM ET
    $SPRC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SciSparc Reinforces its New JV for Targeting Discovery with a Global Expert in the Field of Mitochondrial Transport Proteins

    JV Targets Potential Drugs for Cancers and Infectious Diseases Tel Aviv, Israel, June 15, 2022 (GLOBE NEWSWIRE) --  SciSparc Ltd. (NASDAQ:SPRC) (the "Company" or "SciSparc"), a specialty, clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, today announced the appointment of Prof. Ciro Leonardo Pierri as special advisor for MitoCareX Bio Ltd. ("MitoCareX Bio"), SciSparc's recently established joint venture ("JV") for the discovery and development of potential drugs for cancers, infectious diseases and other life-threatening conditions. Prof. Pierri is a biochemist and serves as an associate professor at the U

    6/15/22 8:30:00 AM ET
    $SPRC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Prof. Avi Schroeder Joins SciSparc's Scientific Advisory Board to Support the Company's Development of SCI-160 for Treating Pain

    Prof. Schroeder to advise on SCI-160 formulation development to enhance biological effect and extended effect duration TEL AVIV, Israel, March 30, 2022 (GLOBE NEWSWIRE) -- SciSparc Ltd. (NASDAQ:SPRC), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system (the "Company" or "SciSparc"), today announced the appointment of Professor Avi Schroeder as a member of the Company's Scientific Advisory Board (SAB). As a member of the SAB, Prof. Schroeder will support the development of the Company's top-tier, proprietary, investigational drug candidate SCI-160 program for the treatment of pain. Prof. Schroed

    3/30/22 8:30:00 AM ET
    $SPRC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SPRC
    Financials

    Live finance-specific insights

    View All

    SciSparc Adopts Limited Duration Shareholder Rights Plan

    TEL AVIV, Israel, Nov. 28, 2023 (GLOBE NEWSWIRE) -- SciSparc Ltd. (NASDAQ:SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the central nervous system, announced today that its Board of Directors (the "Board") has unanimously adopted a limited duration shareholder rights plan (the "Rights Plan"), effective immediately. "Today we announced exciting positive results from our weight loss and metabolic disorder program with our proprietary psychedelic-based treatment," said Oz Adler, SciSparc's Chief Executive Officer. "Unfortunately, SciSparc, like many other clinical-stag

    11/28/23 8:55:00 AM ET
    $SPRC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SciSparc Signs Non-Binding Letter of Intent to Merge with Leading Vehicle Importer Company in Israel

    SciSparc seeks to scale up revenues and will consider transferring its pharmaceutical activities to a separate legal entity and exploring the possibility of dividend distribution TEL AVIV, Israel, Nov. 22, 2023 (GLOBE NEWSWIRE) -- SciSparc Ltd. (NASDAQ:SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the central nervous system, announced today the signing of a non-binding letter of intent to merge with a leading vehicle importer company in Israel (the "Target Company"). This merger (the "Merger) is expected to be consummated by means of a reverse triangular merger, pursua

    11/22/23 7:42:00 AM ET
    $SPRC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SciSparc Announces Expected Implementation of 1-for-26 Reverse Share Split

    Following the reverse share split, the Company will have approximately 521,090 Ordinary Shares issued and outstanding TEL AVIV, Israel, Sept. 27, 2023 (GLOBE NEWSWIRE) --  SciSparc Ltd. (NASDAQ:SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the central nervous system, announces today that its previously announced reverse share split of its issued and outstanding ordinary shares, no par value at a ratio of 1-for-26, is expected to be implemented after market close today. The Company's Ordinary Shares will begin trading on the Nasdaq Capital Market on a post-split basis at

    9/27/23 7:58:00 AM ET
    $SPRC
    Biotechnology: Pharmaceutical Preparations
    Health Care